Canada: SCOTUS: "On Sale" Bar Unchanged And Still Covers Secret Sales

Last Updated: January 30 2019
Article by H. Samuel Frost

In a concise opinion the US Supreme Court had no difficulty in finding that the scope of the 'on sale' bar is unchanged by the AIA (America Invents Act) holding:

The patent statute in force immediately before the AIA included an on-sale bar. This Court's precedent interpreting that provision supports the view that a sale or offer of sale need not make an invention available to the public to constitute invalidating prior art. The Federal Circuit had made explicit what was implicit in this Court's pre-AIA precedent, holding that "secret sales" could invalidate a patent. Given this settled pre-AIA precedent, the Court applies the presumption that when Congress reenacted the same "on sale" language in the AIA, it adopted the earlier judicial construction of that phrase. The addition of the catchall phrase "or otherwise available to the public" is not enough of a change for the Court to conclude that Congress intended to alter the meaning of "on sale." (citations omitted)

Helsinn Healthcare S. A. (Helsinn) is a Swiss pharmaceutical company that acquired the right to develop palonosetron, the active ingredient in a drug Aloxi. Helsinn entered into two agreements with MGI Pharma, Inc. (MGI), a Minnesota pharmaceutical company, as its marketing partner for its palonosetron product: a license agreement and a supply and purchase agreement.

Both agreements included dosage information and required MGI to keep confidential any proprietary information received under the agreements. Helsinn and MGI announced the agreements in a joint press release, and MGI also reported the agreements to the Securities and Exchange Commission, without disclosing the specific dosage formulations covered by the agreements.

Nearly two years after the agreements were made, Helsinn's filed a first provisional patent application on Jan 30, 2003, followed by a series of later applications. A fourth application in this series was filed in May 2013, and issued as U. S. Patent No. 8,598,219 ('219 patent). The '219 patent covers a fixed dose of 0.25 mg of palonosetron in a 5 ml solution. By virtue of its effective date, the '219 patent is governed by the AIA.

Both the pre-AIA and AIA include an "on-sale" provision, present in AIA ァ102(a)(1) as:

"A person shall be entitled to a patent unless . . . the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention." (emphasis added).

While the AIA made numerous significant revisions to the novelty provisions, for the present case, the critical change was the inclusion of the catchall "otherwise available to the public".

As we reported, The District Court determined that the "on sale" provision did not apply. It concluded that, under the AIA, an invention is not "on sale" unless the sale or offer in question made the claimed invention available to the public. The Federal Circuit reversed. It concluded that "if the existence of the sale is public, the details of the invention need not be publicly disclosed in the terms of sale" to fall within the AIA's on sale bar. Because the sale between Helsinn and MGI was publicly disclosed, it held that the on-sale bar applied.

Quoting from various early decisions, the Supreme Court noted that to further the goal of "motivating innovation and enlightenment" while also "avoiding monopolies that unnecessarily stifle competition", Congress has imposed several conditions on the "limited opportunity to obtain a property right in an idea". One such condition is the on-sale bar, which reflects Congress' "reluctance to allow an inventor to remove existing knowledge from public use" by obtaining a patent covering that knowledge. (Explaining from another decision that "it would materially retard the progress of science and the useful arts" to allow an inventor to "sell his invention publicly" and later "take out a patent" and "exclude the public from any farther use than what should be derived under it".)

The Court observed that Congress enacted the AIA in 2011 against the backdrop of a substantial body of law interpreting ァ102's on-sale bar. The Court further observed that while "this Court has never addressed the precise question presented in this case, our precedents suggest that a sale or offer of sale need not make an invention available to the public". It further noted that The Federal Circuit has made explicit what was implicit in the Court's precedents, i.e. it has long held that "secret sales" can invalidate a patent. Referring to oral arguments of amicus United States, it noted that: if "on sale" had a settled meaning before the AIA was adopted, then adding the phrase "or otherwise available to the public" to the statute "would be a fairly oblique way of attempting to overturn" that "settled body of law".

Accordingly, the Court found that; "given that the phrase "on sale" had acquired a well-settled meaning when the AIA was enacted, we decline to read the addition of a broad catchall phrase to upset that body of precedent".

At least one amicus brief argued that restricting the novelty provision to only activities that disclose the invention aligns the US with the absolute novelty standard present in most major industrial countries. While this is correct, a provision ensnaring non-disclosing sales or commercial use is not incompatible with an absolute novelty standard. The novelty provision of South African patent law includes "inventions used secretly on a commercial scale in South Africa before the filing date (priority date)".

Aside from the geographical limitation, such a two part test, based on public disclosure and commercial use, arguably provides a more level playing field for all inventions; all patent applications must then be filed before the first public disclosure AND first commercial use (without considering any applicable grace period). A novelty standard based solely on a disclosure to the public test may well treat all inventions equally, in terms of public disclosures. However, considered from the standpoint of commercial exploitation, it simply divides inventions into those that can be exploited without public disclosure before filing, and those that cannot. Commercial exploitation of nearly all mechanical inventions results in public disclosure so such inventions cannot practically be exploited before the critical date; on the other hand, many technologies, such as some process inventions, can be extensively exploited in secret without disclosing the invention.

Interestingly, Canada is believed to be the only country that has expressly eliminated an "on sale" provision from its patent law, over 20 year ago, that was worded very similarly to the current US provision. The present Canadian novelty standard is based solely on disclosing the invention so as to make it available to the public, aligning Canadian law with prevailing international norms which some suggest was the intent with the AIA.

While the decision is clear, it is suggested that the exact scope of the "on sale" bar may still cause difficulties and may require further clarification by the courts. A broad provision, based on a principle not a specific activity, such as "commercial exploitation", would surely make it much easier for a court to find that any activity, if it amounted to "commercial exploitation", triggers the provision. There are many newer inventions where commercial exploitation may be far removed from simple sale of a patented, physical product. For example, many computer related inventions, assuming they clear the patentability hurdle of ァ101, may be exploited by delivering a service, which may be a service over the internet, so that what has been "on sale" is not a physical product and is some steps removed from the patented invention.

A further potential difficulty, that did not need to be addressed in this case, is that the statute makes no distinction between "on sale" activities of the inventor and those of a third party. The pre-AIA ァ102, as indicated in its heading: CONDITIONS FOR PATENTABILITY; NOVELTY AND LOSS OF RIGHT TO PATENT, at least included the LOSS OF RIGHT concept, which provides a basis for distinguishing between the rights of the inventor and third parties. To protect third party rights, AIA includes ァ273 "The Defense to Infringement" provision; in drafting this, the clear premise is that prior third party "commercial use" would not be invalidating prior art. However, it was likely drafted on the interpretation that all secret prior "commercial use", irrespective of who carried it out, would not be included in the prior art, due to the effect of the catchall "otherwise available to the public". It can be noted that ァ273 uses the term "commercial use", rather than "on sale" which, as suggested, is surely a more inclusive term that will readily enable courts to find that it covers all relevant uses of modern technology.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

H. Samuel Frost
Similar Articles
Relevancy Powered by MondaqAI
Goodmans LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Goodmans LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Sign Up
Gain free access to lawyers expertise from more than 250 countries.
Email Address
Company Name
Confirm Password
Mondaq Newsalert
Select Topics
Select Regions
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq痴 use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor痴 own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq痴 Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq痴 Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq痴 right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions